Beijing Tong Ren Tang Chinese Medicine Full Year 2024 Earnings: Misses Expectations

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Full Year 2024 Results

Key Financial Results

• Revenue: HK$1.61b (up 5.7% from FY 2023).
• Net income: HK$500.3m (down 7.4% from FY 2023).
• Profit margin: 31% (down from 35% in FY 2023). The decrease in margin was driven by higher expenses.
• EPS: HK$0.60 (down from HK$0.65 in FY 2023).

We've discovered 2 warning signs about Beijing Tong Ren Tang Chinese Medicine. View them for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beijing Tong Ren Tang Chinese Medicine Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) also missed analyst estimates by 10%.

The primary driver behind last 12 months revenue was the Hong Kong segment contributing a total revenue of HK$1.27b (79% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to HK$300.2m (53% of total expenses). Explore how 3613's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 9.5% p.a. on average during the next 2 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Beijing Tong Ren Tang Chinese Medicine you should be aware of, and 1 of them shouldn't be ignored.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.